HyperuricemiaNCT06876909
Clinical Effect Observation of Barley Green Intervention in Hyperuricemia Population and Related Mechanism Study of Xanthine Oxidase
A study testing barley green in people with Hyperuricemia, run by Peking University People's Hospital at 1 site in China.
Trial summary
This study aims to explore the changes in metabolic-related indicators in patients with hyperuricemia under the intervention of barley green, reveal the clinical effect of barley green in regulating uric acid metabolism, and preliminarily clarify the mechanism of barley green influencing uric acid metabolism through… Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Hyperuricemia
- What is being tested?
- barley green
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 90 participants
- Where
- 1 siteChina
- Study dates
- 26 Aug 2021to 30 Jun 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Aged 18 to 65 years old; under a normal purine diet, the fasting blood uric acid level on two different days: 420 μmol/L < blood uric acid < 540 μmol/L (for men), 360 μmol/L < blood uric acid < 540 μmol/L (for women); willing to accept the assessment and sign the informed consent.
Who cannot join
- ① Patients currently receiving drug treatment for hyperuricemia;
- Patients with diseases affecting food digestion and absorption (such as chronic diarrhea, constipation, severe digestive tract inflammation, active peptic ulcers, post-gastrointestinal resection, cholecystitis/cholecystectomy, etc.);
- Patients with cardiovascular and cerebrovascular diseases, grade 3 hypertension, chronic hepatitis, malignant tumors, anemia (hemoglobin value below the normal reference range), mental disorders and memory impairment, epilepsy, etc.;
- Patients simultaneously receiving other functional food nutritional support (plant active substances, health foods);
- Patients with abnormal liver function (alanine aminotransferase or/and aspartate aminotransferase exceeding 3 times the upper limit of the normal value); patients with abnormal kidney function (serum creatinine exceeding the upper limit of the normal value);
- Patients with active pulmonary tuberculosis, AIDS and other infectious diseases; ⑦ Patients with severe allergies to the ingredients of the study nutritional product;
- Pregnant or lactating women;
- Patients with limb disabilities and those deemed unsuitable for participation in the study by the clinical doctor (for example, patients with severe diseases not listed in the exclusion criteria); ⑩ Patients with gouty arthritis attacks ≥ 2 times; ⑪ Patients with one gouty arthritis attack and blood uric acid > 480 μmol/L, or combined with any of the following: age < 40 years old, evidence of tophi or urate deposition in the joint cavity, uric acid nephrolithiasis or renal function impairment (eGFR ≤ 89 ml/(min·1.73 m²)), hypertension, impaired glucose tolerance or diabetes, dyslipidemia (any of the four lipid indicators exceeding the normal reference range), obesity (BMI ≥ 28 kg/m²), coronary heart disease, stroke, heart failure; ⑫ Patients with blood uric acid > 480 μmol/L and combined with any of the following: uric acid nephrolithiasis or renal function impairment (eGFR ≤ 89 ml/(min·1.73 m²)), hypertension, impaired glucose tolerance or diabetes, dyslipidemia (any of the four lipid indicators exceeding the normal reference range), obesity (BMI ≥ 28 kg/m²), coronary heart disease, stroke, heart failure.
Trial locations and contacts
1 site in 1 country.
China1 site
Peking University People's Hospital
Beijing, Xicheng District, 100044
About this study
This study aims to explore the changes in metabolic-related indicators in patients with hyperuricemia under the intervention of barley green, reveal the clinical effect of barley green in regulating uric acid metabolism, and preliminarily clarify the mechanism of barley green influencing uric acid metabolism through in vitro experiments related to xanthine oxidase. This study plans to recruit patients with hyperuricemia who visit the clinical nutrition department and rheumatology and immunology department of Peking University People's Hospital, randomly dividing them into an intervention group and a control group. The intervention group will take barley green plus a balanced diet plan, while the control group will only be given a balanced diet plan. General clinical data will be collected, and nutritional measurements will be conducted. Venous blood will be drawn for the determination of uric acid metabolism-related indicators, xanthine oxidase activity, and inflammatory factor levels. The differences in uric acid and related metabolic indicators, as well as xanthine oxidase activity, between the two groups will be observed and compared to provide a scientific basis for the clinical application of barley green in non-pharmacological intervention and medical nutrition therapy for hyperuricemia.
- Conditions
- Hyperuricemia
- Being tested
- barley green
- Medical subject headings
- Hyperuricemia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
barley greenDietary supplement
Oral administration: 30 minutes before meals Dosage: 4 g powder, 5 g tablet Frequency: 2 times a day
| Study group | Role | What they receive |
|---|---|---|
| control group | No intervention | Not described |
| intervention group | Experimental | Not described Receives: Dietary Supplement: barley green |
What is being measured
The primary outcome is the main question the study is designed to answer.
uric acid levels in umol/L
Uric acid levels were measured by blood samples at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Measured: From enrollment to the end of treatment at 12 weeks
Secondary outcomes (36)
Xanthine oxidase activity in ng/mL
Xanthine oxidase activity was measured by blood samples at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Measured: From enrollment to the end of treatment at 12 weeks
erythrocyte sedimentation rate in mm/h
Erythrocyte sedimentation rates were measured by blood samples at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Measured: From enrollment to the end of treatment at 12 weeks
antinuclear antibody in semi-quantitative
Antinuclear antibodies were measured by blood samples at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Measured: From enrollment to the end of treatment at 12 weeks
blood glucose in mmol/L
Blood glucoses were measured by blood samples at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Measured: From enrollment to the end of treatment at 12 weeks
total cholesterol in mmol/L
Total cholesterols were measured by blood samples at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Measured: From enrollment to the end of treatment at 12 weeks
triglycerides in mmol/L
Triglycerides were measured by blood samples at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Measured: From enrollment to the end of treatment at 12 weeks
high-density lipoprotein cholesterol in mmol/L
High-density lipoprotein cholesterols were measured by blood samples at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Measured: From enrollment to the end of treatment at 12 weeks
low-density lipoprotein cholesterol in mmol/L
Low-density lipoprotein cholesterols were measured by blood samples at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Measured: From enrollment to the end of treatment at 12 weeks
C-reactive protein in mg/L
C-reactive proteins were measured by blood samples at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Measured: From enrollment to the end of treatment at 12 weeks
white blood cell count in 10^9/L
White blood cell counts were measured by blood samples at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Measured: From enrollment to the end of treatment at 12 weeks
leptin level in pg/mL
Leptin levels were measured by blood samples at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Measured: From enrollment to the end of treatment at 12 weeks
adiponectin level in ug/mL
Adiponectin levels were measured by blood samples at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Measured: From enrollment to the end of treatment at 12 weeks
IL-1β in pg/mL
IL-1β levels were measured by blood samples at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Measured: From enrollment to the end of treatment at 12 weeks
IL-2 in pg/mL
IL-2 levels were measured by blood samples at two time points: the day of enrollment and 12 weeks after enrollment.
Measured: From enrollment to the end of treatment at 12 weeks
IL-4 in pg/mL
IL-4 levels were measured by blood samples at two time points: the day of enrollment and 12 weeks after enrollment.
Measured: From enrollment to the end of treatment at 12 weeks
IL-6 in pg/mL
IL-6 levels were measured by blood samples at two time points: the day of enrollment and 12 weeks after enrollment.
Measured: From enrollment to the end of treatment at 12 weeks
IL-10 in pg/mL
IL-10 levels were measured by blood samples at two time points: the day of enrollment and 12 weeks after enrollment.
Measured: From enrollment to the end of treatment at 12 weeks
IFN-γ in pg/mL
IFN-γ levels were measured by blood samples at two time points: the day of enrollment and 12 weeks after enrollment.
Measured: From enrollment to the end of treatment at 12 weeks
TNF-α in pg/mL
TNF-α levels were measured by blood samples at two time points: the day of enrollment and 12 weeks after enrollment.
Measured: From enrollment to the end of treatment at 12 weeks
height in centimeters
Height in centimeters were measured by Manual Height Ruler at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Measured: From enrollment to the end of treatment at 12 weeks
weight in kilograms
Weight in kilograms were measured by the Inbody 770 instrument at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Measured: From enrollment to the end of treatment at 12 weeks
BMI in kg/m^2
Weight and height will be combined to report BMI in kg/m^2 at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Measured: From enrollment to the end of treatment at 12 weeks
body fat rate in %
Body fat rates were measured by the Inbody 770 instrument at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Measured: From enrollment to the end of treatment at 12 weeks
muscle mass in kilograms
Muscle masses were measured by were measured by the Inbody 770 instrument at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Measured: From enrollment to the end of treatment at 12 weeks
basal metabolic rate in kcal
Basal metabolic rates were measured by the Inbody 770 instrument at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Measured: From enrollment to the end of treatment at 12 weeks
skeletal muscle mass in kilograms
Skeletal muscle masses were measured by the Inbody 770 instrument at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Measured: From enrollment to the end of treatment at 12 weeks
blood pressure in mmHg
Blood pressures were measured by electronic blood pressure monitor at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Measured: From enrollment to the end of treatment at 12 weeks
waist circumference in millimeters
Waist circumferences were measured by tape measure at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Measured: From enrollment to the end of treatment at 12 weeks
hip circumference in millimeters
Hip circumferences were measured by tape measure at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Measured: From enrollment to the end of treatment at 12 weeks
upper arm circumference in millimeters
Upper arm circumferences were measured by tape measure at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Measured: From enrollment to the end of treatment at 12 weeks
left hand grip strength in pound-force
Left hand grip strengths were measured by grip dynamometer at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Measured: From enrollment to the end of treatment at 12 weeks
right hand grip strength in pound-force
Right hand grip strengths were measured by grip dynamometer at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Measured: From enrollment to the end of treatment at 12 weeks
triceps skinfold thickness in millimeters
Triceps skinfold thicknesses were measured by skin fold thickness gauge at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Measured: From enrollment to the end of treatment at 12 weeks
subscapular horn skinfold thickness in millimeters
Subscapular horn skinfold thicknesses were measured by skin fold thickness gauge at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Measured: From enrollment to the end of treatment at 12 weeks
abdominal skinfold thickness in millimeters
Abdominal skinfold thicknesses were measured by skin fold thickness gauge at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Measured: From enrollment to the end of treatment at 12 weeks
food intake dose in grams
Data of food intake doses were taken by food frequency questionnaire and 3-day food diary at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
Measured: From enrollment to the end of treatment at 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Mar 2025
- Study start26 Aug 2021
- Primary completion30 Jun 2024
- Study completion30 Jun 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for HyperuricemiaStudies of the same condition, open and under way.
- More trials run by Peking University People's HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 90 participants (actual)
Sponsor and investigators
- Lead sponsor
- Peking University People's Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Cui Mingxuan, Peking University People's Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06876909
- Sponsor's protocol ID
- 2021PHB074-001
- Status last verified
- Feb 2025
- First submitted
- 25 Feb 2025
- Last updated
- 11 Aug 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Cui M, Shao L, Zhao S, Guo Q, Liu X, Liu P. Effects of barley green on uric acid, inflammatory factors, xanthine oxidase activity and body composition of patients with hyperuricemia: a randomized controlled trial. Front Nutr. 2025 Oct 31;12:1684829. doi: 10.3389/fnut.2025.1684829. eCollection 2025.
PubMed 41245398
Study at a glance
From the registry record, last updated by the sponsor on 11 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Effect Observation of Barley Green Intervention in Hyperuricemia Population and Related Mechanism Study of Xanthine Oxidase
- ClinicalTrials.gov ID
- NCT06876909
- Acronym / sponsor ID
- 2021PHB074-001
- Conditions
- Hyperuricemia
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 90 participants (actual)
- Lead sponsor
- Peking University People's HospitalUniversity, hospital or other
- Study start
- 26 Aug 2021 (actual)
- Primary completion
- 30 Jun 2024 (actual)
- Study completion
- 30 Jun 2024 (actual)
- First posted
- 14 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to explore the changes in metabolic-related indicators in patients with hyperuricemia under the intervention of barley green, reveal the clinical effect of barley green in regulating uric acid metabolism, and preliminarily clarify the mechanism of barley green influencing uric acid metabolism through in vitro experiments related to xanthine oxidase. This study plans to recruit patients with hyperuricemia who visit the clinical nutrition department and rheumatology and immunology department of Peking University People's Hospital, randomly dividing them into an intervention group and a control group. The intervention group will take barley green plus a balanced diet plan, while the control group will only be given a balanced diet plan. General clinical data will be collected, and nutritional measurements will be conducted. Venous blood will be drawn for the determination of uric acid metabolism-related indicators, xanthine oxidase activity, and inflammatory factor levels. The differences in uric acid and related metabolic indicators, as well as xanthine oxidase activity, between the two groups will be observed and compared to provide a scientific basis for the clinical application of barley green in non-pharmacological intervention and medical nutrition therapy for hyperuricemia.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| control group | No intervention | – |
| intervention group | Experimental | Dietary Supplement: barley green |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Aged 18 to 65 years old; under a normal purine diet, the fasting blood uric acid level on two different days: 420 μmol/L < blood uric acid < 540 μmol/L (for men), 360 μmol/L < blood uric acid < 540 μmol/L (for women); willing to accept the assessment and sign the informed consent.
Key exclusion criteria (8 listed)
- ① Patients currently receiving drug treatment for hyperuricemia;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| barley greenOral administration: 30 minutes before meals Dosage: 4 g powder, 5 g tablet Frequency: 2 times a day | Dietary supplement | intervention group |
Primary outcome
uric acid levels in umol/L
Time frame: From enrollment to the end of treatment at 12 weeks
Uric acid levels were measured by blood samples at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment.
36 secondary outcomes
Xanthine oxidase activity in ng/mL
Time frame: From enrollment to the end of treatment at 12 weeks
erythrocyte sedimentation rate in mm/h
Time frame: From enrollment to the end of treatment at 12 weeks
antinuclear antibody in semi-quantitative
Time frame: From enrollment to the end of treatment at 12 weeks
blood glucose in mmol/L
Time frame: From enrollment to the end of treatment at 12 weeks
total cholesterol in mmol/L
Time frame: From enrollment to the end of treatment at 12 weeks
triglycerides in mmol/L
Time frame: From enrollment to the end of treatment at 12 weeks
high-density lipoprotein cholesterol in mmol/L
Time frame: From enrollment to the end of treatment at 12 weeks
low-density lipoprotein cholesterol in mmol/L
Time frame: From enrollment to the end of treatment at 12 weeks
C-reactive protein in mg/L
Time frame: From enrollment to the end of treatment at 12 weeks
white blood cell count in 10^9/L
Time frame: From enrollment to the end of treatment at 12 weeks
leptin level in pg/mL
Time frame: From enrollment to the end of treatment at 12 weeks
adiponectin level in ug/mL
Time frame: From enrollment to the end of treatment at 12 weeks
IL-1β in pg/mL
Time frame: From enrollment to the end of treatment at 12 weeks
IL-2 in pg/mL
Time frame: From enrollment to the end of treatment at 12 weeks
IL-4 in pg/mL
Time frame: From enrollment to the end of treatment at 12 weeks
IL-6 in pg/mL
Time frame: From enrollment to the end of treatment at 12 weeks
IL-10 in pg/mL
Time frame: From enrollment to the end of treatment at 12 weeks
IFN-γ in pg/mL
Time frame: From enrollment to the end of treatment at 12 weeks
TNF-α in pg/mL
Time frame: From enrollment to the end of treatment at 12 weeks
height in centimeters
Time frame: From enrollment to the end of treatment at 12 weeks
weight in kilograms
Time frame: From enrollment to the end of treatment at 12 weeks
BMI in kg/m^2
Time frame: From enrollment to the end of treatment at 12 weeks
body fat rate in %
Time frame: From enrollment to the end of treatment at 12 weeks
muscle mass in kilograms
Time frame: From enrollment to the end of treatment at 12 weeks
basal metabolic rate in kcal
Time frame: From enrollment to the end of treatment at 12 weeks
skeletal muscle mass in kilograms
Time frame: From enrollment to the end of treatment at 12 weeks
blood pressure in mmHg
Time frame: From enrollment to the end of treatment at 12 weeks
waist circumference in millimeters
Time frame: From enrollment to the end of treatment at 12 weeks
hip circumference in millimeters
Time frame: From enrollment to the end of treatment at 12 weeks
upper arm circumference in millimeters
Time frame: From enrollment to the end of treatment at 12 weeks
left hand grip strength in pound-force
Time frame: From enrollment to the end of treatment at 12 weeks
right hand grip strength in pound-force
Time frame: From enrollment to the end of treatment at 12 weeks
triceps skinfold thickness in millimeters
Time frame: From enrollment to the end of treatment at 12 weeks
subscapular horn skinfold thickness in millimeters
Time frame: From enrollment to the end of treatment at 12 weeks
abdominal skinfold thickness in millimeters
Time frame: From enrollment to the end of treatment at 12 weeks
food intake dose in grams
Time frame: From enrollment to the end of treatment at 12 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Aug 2025.
- Derived from this study: PubMed 41245398Cui M, Shao L, Zhao S, Guo Q, Liu X, Liu P. Effects of barley green on uric acid, inflammatory factors, xanthine oxidase activity and body composition of patients with hyperuricemia: a randomized controlled trial. Front Nutr. 2025 Oct 31;12:1684829. doi: 10.3389/fnut.2025.1684829. eCollection 2025.
- Individual participant dataSharing planned: Undecided
Related trials for Hyperuricemia
Active, not recruitingObservational study
Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD)
Hyperuricemia and MAFLD
RecruitingPhase 2
Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and Hyperuricaemia
Chronic Kidney Disease
RecruitingPhase 3
A Study of Dotinurad Versus Allopurinol in Participants With Gout
Gout
RecruitingPhase 3
A Study of Dotinurad Versus Allopurinol in Tophaceous Gout
Tophaceous Gout
Not yet recruitingPhase 3
Combined Metabolic Activator Supplementation in Subjects Diagnosed With Gout
Gout Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing barley green in people with Hyperuricemia, run by Peking University People's Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
uric acid levels in umol/L (time frame: From enrollment to the end of treatment at 12 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06876909, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Aug 2025.